Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.
Benjamin J LermanYimei LiCecilia CarlowiczMeaghan P GrangerThomas CashArhanti SadanandKatherine M SomersAeesha RanavayaBrian D WeissMichelle ChoeJennifer H FosterNavin R PintoDaniel A MorgensternMargarida Simão RafaelKeri A StrebyRachel N ZenoRajen J ModySahr YazdaniAmi Vijay DesaiMargaret E MacySuzanne ShustermanSara M FedericoRochelle BagatellPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Approximately half of patients receiving I/T/DIN/GM-CSF for relapsed HRNB had objective responses. Patients with initial SD were unlikely to have an objective response, but > 1 of 3 patients with MR/PR on first evaluation ultimately had complete response. I/T/DIN/GM-CSF was associated with extended PFS in responders both during and after discontinuation of treatment. This study establishes a new comparator for response and survival in patients with relapsed HRNB.